Pressmeddelanden
REG
Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025
Summary of the Interim ReportThe second quarter of 2025 has been defined by intense preparation for one of the most important milestones in Coegin Pharma's history - the upcoming...
Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product
The company is pleased to inform that the commercialisation of the first Follicopeptide-based product, expected by the end of this year, is firmly on schedule. Commercial scale p...
REG
Coegin Pharma ändrar språk för informationsgivning till engelska
Coegin Pharma meddelar härmed att bolaget ändrar språk för informationsgivning till endast engelska. Detta innebär att finansiella rapporter och pressmeddelanden endast kommer at...
REG
Coegin Pharma changes language for company communication to English
Coegin Pharma hereby announces that the company will change its language for communication to English only. This means that financial reports and press releases will henceforth b...
Coegin Pharma har sänkt produktkostnaden med 80 procent - närmar sig lansering av Follicopeptide
Coegin Pharma närmar sig lansering av sin första produkt för hårtillväxt baserad på Follicopeptide. Genom ett målinriktat utvecklingsarbete har bolaget hittills sänkt kostnaden f...
Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide
Coegin Pharma is approaching the launch of its first hair growth product based on Follicopeptide. Through focused development efforts, the company has so far reduced the cost of...
Rapporter
Video
Finansiell kalender
Delårsrapport Q3 2025
Delårsrapport
Bokslutskommuniké 2025
Bokslutskommuniké
Om Coegin Pharma
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs ()
Förändring ()
